Navigation Links
Experimental drug reverses key cognitive deficits, pathology in Alzheimer's

A new drug that enhances the activity of a key brain cell receptor involved in Alzheimer's disease (AD) reverses learning and memory deficits in mice engineered to have pathological hallmarks of the disease. What's more, the drug, called AF267B, reduces both of the pathologies--the brain-clogging buildup of protein "amyloid plaque" outside brain cells and the protein "neurofibrillary tangles" inside the cells.

In an article in the March 2, 2006, issue of Neuron, Dr. Frank LaFerla of the University of California, Irvine and his colleagues reported the first in vivo studies of the drug's effects. AF267B was developed by coauthor Abraham Fisher to activate particular receptors for the neurotransmitter acetylcholine. These specific receptors, called M1 receptors, are abundant in areas of the brain--the cortex and hippocampus--known to develop severe deposits of plaques and tangles in AD patients. Dysfunction in acetylcholine receptors has been shown to be characteristic of early stages of AD.

Receptors are proteins on the neuronal surface that are triggered by the chemical signals called neurotransmitters. This triggering initiates such cellular responses as the wave of electrical excitation of a nerve impulse.

As an animal model of AD, the researchers used a "triple knockout" mouse in which three key genes involved in normal brain protein processing pathways had been knocked out, creating both amyloid plaques and neurofibrillary tangles.

In their experiments, the researchers gave the knockout mice eight weeks of daily doses of AF267B and tested the animals' learning and memory abilities. One test involved measuring how well the treated animals could learn to find a submerged platform in a tank of murky water. This test is known to depend on the function of the hippocampus. The researchers found that the treated mice performed significantly better than untreated knockout mice on the task.

Significantly, found the researchers, the
'"/>

Source:Cell Press


Page: 1 2

Related biology news :

1. NIAID Initiates Trial of Experimental Avian Flu Vaccine
2. Experimental shingles vaccine proves effective in nationwide study
3. Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
4. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
5. Experimental RNA-based drug kills prostate cancer cells effectively and safely
6. Experimental vaccine protects lab animals against several strains of H5N1
7. Experimental vaccine protects mice against deadly 1918 flu virus
8. Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy
9. Experimental vaccine given during pregnancy reduces stillbirths from common virus
10. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
11. Genetic therapy reverses nervous system damage in animal model of inherited human disease
Post Your Comments:
(Date:3/3/2015)... 3, 2015 Cryoport, Inc. (OTCBB: ... cryogenic logistics solutions for the life sciences ... cell lines, clinical research organizations, vaccine manufacturers, ... the expansion of its relationship with ... Hutch") Clinical Research Division with the inclusion ...
(Date:3/2/2015)... Calif. , March 2, 2015 ... leading developer of human interface solutions, today announced ... that is designed to enable rapid and secure ... ID™ module for gaming is a turnkey solution ... the ability to quickly integrate fingerprint ID solutions ...
(Date:3/2/2015)... March 2, 2015  Businesses have a new ... company Tharon Rankins Enterprises has announced the launch ... ultra-safe way for businesses to protect their customers, ... Beconux is a biometric transaction ... Functioning similarly to an ATM machine, the new ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Personal Data Protection Company Launches New Product 2
... Bethesda, Md. (July 27, 2011)Roux-en-Y gastric bypass, the most ... is currently considered the most effective therapy for morbid ... stomach is reduced to a small pouch and connected ... massive amounts of weight. However, the reasons behind this ...
... Md. "Brain cap" technology being developed at the ... into motion. Associate Professor of Kinesiology Jos ,Pepe, L. ... cap with neural interface software that soon could be ... and even digital avatars. "We are on track ...
... patients may view their tumors as parasites taking over their ... Duesberg, a molecular and cell biology professor at the University ... said. Each one is a new species that, like most ... independently and often to the detriment of its host. ...
Cached Biology News:Study suggests weight loss from gastric bypass may be partly due to dietary fat aversion 2Study suggests weight loss from gastric bypass may be partly due to dietary fat aversion 3UMD brain cap technology turns thought into motion 2UMD brain cap technology turns thought into motion 3UMD brain cap technology turns thought into motion 4UMD brain cap technology turns thought into motion 5Are cancers newly evolved species? 2Are cancers newly evolved species? 3Are cancers newly evolved species? 4Are cancers newly evolved species? 5
(Date:3/2/2015)... Md. , March 2, 2015 ... -based biotechnology company focusing on the research ... next generation antibody agents based upon a novel ... a 2015 Life Sciences Impact Grant Award from ... The grant, created by MCDED, is awarded to ...
(Date:3/2/2015)... CORAL SPRINGS, Florida , March 2, 2015 ... products, science-based pharmaceuticals and healthy whole food nutrition ... for treatments of lifestyle related disorders such as ... illnesses and health concerns.  Nutraceutical and Biotech Companies ... RIBT ), Amira Nature Foods Ltd. (NYSE: ...
(Date:3/2/2015)... 2015 VG Life Sciences, Inc., (OTCQB: ... and infectious diseases, announced that the U.S. Patent ... new composition of matter patent covering methods for ... CLIP. U.S. Patent No. 8957031 ... Sciences, VG1177, a synthetic peptide which has the ...
(Date:3/2/2015)... March 02, 2015 Outside GC, the ... announced the addition of Debbie Casey as a member ... the healthcare space. , Debbie has spent ... which with Fresenius Medical Care North America in both ... extensive experience to work with Outside GC’s growing list ...
Breaking Biology Technology:VLP Therapeutics Wins the 2015 Life Sciences Impact Grant Award from the Montgomery County Department of Economic Development 2Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 2Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 3Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 4Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 5Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 6Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 7VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Outside GC Expands Healthcare Team 2
... National Stem,Cell Holding, Inc. (OTC: NHGI) today announced ... at the 16th Annual International,World Congress on Anti-Aging ... -- 19, 2008. Dr. Kenneth Steiner, MD, MBA ... Dr. Steiner will introduce the company,s first,commercial line ...
... July 17 XTL,Biopharmaceuticals Ltd. (Nasdaq: XTLB ... ("AGM") and Extraordinary General Meeting ("EGM") scheduled,for today ... 2008 at,4:00pm and 4:30 pm Israel time, respectively., ... Ltd. ("XTL") is engaged in the development of,therapeutics ...
... BEDFORD, Mass. and MADISON, Wis., July 17 ,Hologic, Inc. ... (Nasdaq:,TWTI) ("Third Wave"), today jointly announced the expiration of ... wholly-owned subsidiary Thunder,Tech Corp. (the "Purchaser") for all outstanding ... period expired, as scheduled, at 12:00,midnight, New York City ...
Cached Biology Technology:National Stem Cell Holding, Inc. (Ticker NHGI) Subsidiary Proteoderm, Inc. Debuts Cosmoceutical Line at the 2008 World Congress on Anti-Aging Medicine 2Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 2Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 3Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 4Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 5
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Human peripheral blood basophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
... an anodized aluminum, solvent-resistant block specially designed ... efficient thermal transfer to samples within the ... HT96 Isothermal Block replaces Cat. No. 71031-3, ... for compatibility with robotic applications. The new ...
Biology Products: